We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Cayman CGP 3466 (maleate)
Product Description
CGP 3466 is a GAPDH ligand., Immobilized CGP 3466 binds to GAPDH from rat hippocampus extracts and to purified recombinant rabbit muscle GAPDH using affinity purification. CGP 3466 reduces PAJU cell apoptosis induced by rotenone (Item No. ). CGP 3466 dose-dependently increases survival of trophically withdrawn PC12 cells, decreases cytosine arabinoside-induced apoptosis of cerebellar granule cells, and increases the number of tyrosine hydroxylase-positive (TH+) mesencephalic dopaminergic neurons in vitro. Oral administration of CGP 3466 (0.14 mg/kg) increases the number of TH+ dopaminergic neurons in a rat model of Parkinsons disease induced by MPTP. It also reduces delayed acquisition in the Morris maze in a 6-OHDA-treated rat model of Parkinsons disease and increases survival in progressive motor neuronopathy (pmn) mice, a genetic model of amyotrophic lateral sclerosis (ALS). Formulations containing CGP 3466 are under clinical investigation for the treatment of Parkinson’s disease and ALS.,
WARNING This product is not for human or veterinary use.
Technical Information
- CGP 3466B
- DMF: 20 mg/mL
- DMSO: 20 mg/mL
- Ethanol: 0.5 mg/mL
- PBS (pH 7.2): 0.5 mg/mL
Shipping & Storage Information
| SKU | CAYM-23362-1 |
|---|---|
| Supplier Part Number | 23362-1 |
| UM | EA |
| UNSPSC | 12352200 |
| Manufacturer | Cayman |
| MSDS URL | Click here |
| Temperature | -20 |
| Refrigerated-Frozen | Y |
| CountryOfOrigin | United States |
| ProductLine | CAYM |
| Qty | 1 |
| MinOrderQty | 1 |
| Weight | 7.000000 |
| Lead Time | 5 |
| Hazardous | N |
| CAS Number | 200189-97-5 |
| Energy Star | No |
| Green | No |
| Controlled | N |